Gamma Biosciences (PRIVATE.GAMMA)

Overall impact
A (89)

Commentary

Gamma Biosciences is a leader for overall positive impact. With an 'A' rating of 88.6 for overall impact (98th percentile compared to all companies), Gamma Biosciences ranks 2nd out of 585 industry peers, behind Genasys, and ahead of Grifols, Biogen, Ionis Pharmaceuticals and 580 others. On top material causes for Gamma Biosciences's industry (Pharmaceuticals & Biotech), Gamma Biosciences performs well in Improved Mental Health (95.7 score), Reduced Use of tobacco (84.2), Disease Eradication (96.4) and 10 other causes where it received an 'A' score. Gamma Biosciences did not receive a 'D' or 'F' rating on any cause.
Impact
Cause PRIVATE.GAMMA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2019
Employees
12
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
California, United States
Share classes
PRIVATE.GAMMA
Description
Operator of a life sciences company intended to provide products and services to support the development and manufacturing of advanced biologic therapies. The company is committed to helping in advancing the science and art of bioprocessing by delivering market-ready innovation and expertise. This enables biopharmaceutical companies and contract development and manufacturing companies to safely bring therapies to patients more quickly and efficiently.
Material causes
Ethos considers the following causes material for Gamma Biosciences, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.